Skip to main content
Journal cover image

Coronary Atherosclerosis, Cardiac Troponin, and Interleukin-6 in Patients With Chest Pain: The PROMISE Trial Results.

Publication ,  Journal Article
Ferencik, M; Mayrhofer, T; Lu, MT; Bittner, DO; Emami, H; Puchner, SB; Meyersohn, NM; Ivanov, AV; Adami, EC; Voora, D; Ginsburg, GS ...
Published in: JACC Cardiovasc Imaging
August 2022

BACKGROUND: Increased inflammation and myocardial injury can be observed in the absence of myocardial infarction or obstructive coronary artery disease (CAD). OBJECTIVES: The authors determined whether biomarkers of inflammation and myocardial injury-interleukin (IL)-6 and high-sensitivity cardiac troponin (hs-cTn)-were associated with the presence and extent of CAD and were independent predictors of major adverse cardiovascular events (MACEs) in stable chest pain. METHODS: Using participants from the PROMISE trial, the authors measured hs-cTn I and IL-6 concentrations and analyzed computed tomography angiography (CTA) images in the core laboratory for CAD characteristics: significant stenosis (≥70%), high-risk plaque (HRP), Coronary Artery Disease Reporting and Data System (CAD-RADS) categories, segment involvement score (SIS), and coronary artery calcium (CAC) score. The primary endpoint was a composite MACE (death, myocardial infarction, or unstable angina). RESULTS: The authors included 1,796 participants (age 60.2 ± 8.0 years; 47.5% men, median follow-up 25 months). In multivariable linear regression adjusted for atherosclerotic cardiovascular disease (ASCVD) risk, hs-cTn was associated with HRP, stenosis, CAD-RADS, and SIS. IL-6 was only associated with stenosis and CAD-RADS. hs-cTn above median (1.5 ng/L) was associated with MACEs in univariable analysis (HR: 2.1 [95% CI: 1.3-3.6]; P = 0.006), but not in multivariable analysis adjusted for ASCVD and CAD. IL-6 above median (1.8 ng/L) was associated with MACEs in multivariable analysis adjusted for ASCVD and HRP (HR: 1.9 [95% CI: 1.1-3.3]; P = 0.03), CAC (HR: 1.9 [95% CI: 1.0-3.4]; P = 0.04), and SIS (HR: 1.8 [95% CI: 1.0-3.2]; P = 0.04), but not for stenosis or CAD-RADS. In participants with nonobstructive CAD (stenosis 1%-69%), the presence of both hs-cTn and IL-6 above median was strongly associated with MACEs (HR: 2.5-2.7 after adjustment for CAD characteristics). CONCLUSIONS: Concentrations of hs-cTn and IL-6 were associated with CAD characteristics and MACEs, indicating that myocardial injury and inflammation may each contribute to pathways in CAD pathophysiology. This association was most pronounced among participants with nonobstructive CAD representing an opportunity to tailor treatment in this at-risk group. (PROspective Multicenter Imaging Study for Evaluation of Chest Pain [PROMISE]; NCT01174550).

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JACC Cardiovasc Imaging

DOI

EISSN

1876-7591

Publication Date

August 2022

Volume

15

Issue

8

Start / End Page

1427 / 1438

Location

United States

Related Subject Headings

  • Troponin I
  • Troponin
  • Risk Factors
  • Risk Assessment
  • Prospective Studies
  • Prognosis
  • Predictive Value of Tests
  • Plaque, Atherosclerotic
  • Myocardial Infarction
  • Middle Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ferencik, M., Mayrhofer, T., Lu, M. T., Bittner, D. O., Emami, H., Puchner, S. B., … Hoffmann, U. (2022). Coronary Atherosclerosis, Cardiac Troponin, and Interleukin-6 in Patients With Chest Pain: The PROMISE Trial Results. JACC Cardiovasc Imaging, 15(8), 1427–1438. https://doi.org/10.1016/j.jcmg.2022.03.016
Ferencik, Maros, Thomas Mayrhofer, Michael T. Lu, Daniel O. Bittner, Hamed Emami, Stefan B. Puchner, Nandini M. Meyersohn, et al. “Coronary Atherosclerosis, Cardiac Troponin, and Interleukin-6 in Patients With Chest Pain: The PROMISE Trial Results.JACC Cardiovasc Imaging 15, no. 8 (August 2022): 1427–38. https://doi.org/10.1016/j.jcmg.2022.03.016.
Ferencik M, Mayrhofer T, Lu MT, Bittner DO, Emami H, Puchner SB, et al. Coronary Atherosclerosis, Cardiac Troponin, and Interleukin-6 in Patients With Chest Pain: The PROMISE Trial Results. JACC Cardiovasc Imaging. 2022 Aug;15(8):1427–38.
Ferencik, Maros, et al. “Coronary Atherosclerosis, Cardiac Troponin, and Interleukin-6 in Patients With Chest Pain: The PROMISE Trial Results.JACC Cardiovasc Imaging, vol. 15, no. 8, Aug. 2022, pp. 1427–38. Pubmed, doi:10.1016/j.jcmg.2022.03.016.
Ferencik M, Mayrhofer T, Lu MT, Bittner DO, Emami H, Puchner SB, Meyersohn NM, Ivanov AV, Adami EC, Voora D, Ginsburg GS, Januzzi JL, Douglas PS, Hoffmann U. Coronary Atherosclerosis, Cardiac Troponin, and Interleukin-6 in Patients With Chest Pain: The PROMISE Trial Results. JACC Cardiovasc Imaging. 2022 Aug;15(8):1427–1438.
Journal cover image

Published In

JACC Cardiovasc Imaging

DOI

EISSN

1876-7591

Publication Date

August 2022

Volume

15

Issue

8

Start / End Page

1427 / 1438

Location

United States

Related Subject Headings

  • Troponin I
  • Troponin
  • Risk Factors
  • Risk Assessment
  • Prospective Studies
  • Prognosis
  • Predictive Value of Tests
  • Plaque, Atherosclerotic
  • Myocardial Infarction
  • Middle Aged